MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $341.94 (184.43% upside)

Current Analysts' Coverage Summary for Intercept Pharmaceuticals (NASDAQ:ICPT)
Show:
DateFirmActionRatingPrice TargetActions
1/29/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Needham & Company LLCReiterated RatingBuy$500.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016WedbushReiterated RatingOutperform$493.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015Leerink SwannReiterated RatingHold$214.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Robert W. BairdReiterated RatingBuy$346.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015JMP SecuritiesLower Price TargetMarket Outperform$348.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015FBR & Co.Reiterated RatingMarket Perform$192.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells FargoInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Bank of AmericaDowngradeNeutral -> Underperform$268.00 -> $157.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015RBC CapitalReiterated RatingOutperform$490.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2015OppenheimerReiterated RatingOutperform$375.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015BarclaysInitiated CoverageOverweight$425.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2015BMO Capital MarketsSet Price TargetBuy$515.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Deutsche BankBoost Price TargetBuy$300.00 -> $400.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Summer StreetReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2014Goldman SachsInitiated CoverageNeutral$265.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/13/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha